Новости "Spinal News International"
BIBA Publishing message
Friday, 31 August 2018
Top stories
Spinal muscular atrophy drug may be effective if started later than previously shown
Nusinersen (Biogen) has previously been shown to be effective in the treatment of spinal muscular atrophy in infants under seven months of age; recent research published in Neurology, the medical journal of the American Academy of Neurology, suggests that the drug may also be effective for muscle control even when treatment is started in children older than seven months.
Quality of life after spinal cord injury: Having independent mobility makes the greatest impact
Independence in mobility is the single most important factor affecting quality of life in patients with traumatic spinal cord injury, reports a study in the American Journal of Physical Medicine & Rehabilitation, the official journal of the Association of Academic Physiatrists.
New therapy spurs nerve fibres to regrow through scar tissue and transmit signals after spinal cord injury in rats
Neuroscientists at UCLA, Harvard University and the Swiss Federal Institute of Technology have identified a three-pronged treatment that triggers axons to regrow after complete spinal cord injury in rodents. In addition to facilitating axon growth through scar tissue, the treatment enabled the transmission of signals across the damaged tissue, the Nature study reports.
Feature
Reducing physician burnout: First destigmatise, then organise
Todd J Albert is surgeon-in-chief at the Hospital for Special Surgery, New York, USA, and is the current president of the Scoliosis Research Society (SRS). At the 25th International Meeting on Advanced Spine Techniques (11–14 July, Los Angeles, USA), hosted by the SRS, Albert gave a stirring keynote address hoping to contribute to and widen the ongoing global discussion concerning physician burn out, and advocating for the adoption of certain individual- and institution-level interventions to help lessen the strain on surgeons’ mental health.
Industry news
Stryker announces definitive agreement to acquire K2M
Stryker has announced a definitive merger agreement to acquire all of the issued and outstanding shares of common stock of K2M Group Holdings, a company specialising in minimally invasive spinal devices, for US$27.50 per share, or total equity value of approximately US$1.4 billion. K2M, which was founded in 2004, has emerged as a key player in the roughly US$10 billion spinal market.
NuVasive unveils spine’s first integrated surgical automation platform
NuVasive has announced the Pulse surgical automation platform has received 510(k) clearance from the US Food and Drug Administration (FDA). Pulse introduces 2D- and 3D-navigation and smart imaging capabilities while integrating NuVasive’s neuromonitoring, surgical planning, radiation reduction and patient-specific rod bending technologies.
French national healthcare system announces exclusive coverage for the iFuse Implant System
SI-Bone has announced that iFuse will be added to the List of Refundable Products and Services in France, meaning that the French National Healthcare System will exclusively cover the iFuse procedure. Through the iFuse Implant System, the product has already been used in the minimally invasive surgical treatment of the sacroiliac (SI) joint.
Events
06–08 September
Society for Minimally Invasive Spine Surgery (SMISS) Annual Forum
Las Vegas, USA
W: www.smissmeeting.org
07–08 September
The 1st Sino-Euro International Orthopedics Summit
Guanghzou, China
W: www.gloryren.com
13–15 September
ISCOS 2018: 57th International Spinal Cord Society Meeting
Sydney, Australia
W: iscos.org.uk
Write to us:
Editor: Suzie Marshall - suzie@bibamedical.com
Advertise with us:
Elizabeth Sutherst - elizabeth@bibamedical.com
You are receiving this email because you subscribed/registered on www.spinalnewsinternational.co
Our mailing address is:
BIBA Medical Ltd,
526 Fulham Road, Fulham, London, SW6 5NR
TEL: +44 (0)20 7736 8788
>
> FAX: +44 (0)20 7736 8283
>
> EMAIL: info@bibamedical.com
>
> © BIBA Medical Ltd is a company registered in England and Wales with company number 2944429. VAT registration number 730 6811 50